Get the Stockscreener App
185.67
0.18%
0.34
After Hours:
185.51
-0.16
-0.09%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $185.67, with a volume of 1.50M.
It is up +0.18% in the last 24 hours and up +0.25% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$185.33
Open:
$185.99
24h Volume:
1.50M
Relative Volume:
0.78
Market Cap:
$287.95B
Revenue:
$60.48B
Net Income/Loss:
$10.40B
P/E Ratio:
55.76
EPS:
3.3297
Net Cash Flow:
$8.05B
1W Performance:
-0.73%
1M Performance:
+0.25%
6M Performance:
+100.25%
1Y Performance:
+161.99%
1-Day Range:
$184.65
$187.10
1-Week Range:
$183.35
$188.72
52-Week Range:
$68.61
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
185.67 | 287.42B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,105.00 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
225.33 | 555.59B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
217.72 | 386.27B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
118.72 | 296.11B | 65.51B | 8.93B | 14.12B | 3.5532 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
AstraZeneca targets year end for COVID-19 vaccine - Edition.mv
AstraZeneca plc stock (GB0009895292): CARES phase 3 data spotlight subgroup benefit after missed end - AD HOC NEWS
AstraZeneca PLC stock (US6549022043): FDA approval for Imfinzi in early bladder cancer adds to US on - AD HOC NEWS
AstraZeneca plc stock (GB0009895292): London-listed pharma group in focus after new CelLBxHealth par - AD HOC NEWS
ASCO26: AstraZeneca’s light chain amyloidosis shows subgroup benefit after Phase III trial - Clinical Trials Arena
CSPC Pharmaceutical receives $1.2 billion upfront payment from AstraZeneca - marketscreener.com
US bank sees positive risk-reward for AstraZeneca ahead of pivotal heart drug trial - Proactive financial news
AstraZeneca highlights data insights from Cares clinical programme - London South East
WINNERS & LOSERS: CelLBxHealth jumps on AstraZeneca partnership - marketscreener.com
CelLBxHealth shares jump on partnership with AstraZeneca - London South East
AstraZeneca's Imfinzi Gets US FDA Nod for Bladder Cancer Combo Therapy - Yahoo Finance UK
CelLBxHealth secures AstraZeneca agreement to provide circulating tumour cell analytics services (CLBX) - Yahoo Finance UK
CelLBxHealth rises 33% after signing AstraZeneca deal - Share Talk
Astrazeneca Obtains US Approval for Imfinzi-based Bladder Cancer Combination Therapy - marketscreener.com
CelLBxHealth shares jump 36% after master services agreement with AstraZeneca - Proactive financial news
Astrazeneca's Imfinzi receives green light from US FDA - Sharecast.com
CelLBxHealth PLC Enters Master Services Agreement With AstraZeneca PLC - marketscreener.com
AstraZeneca’s Imfinzi Plus BCG Approved By FDA For High-risk Bladder Cancer - DirectorsTalk Interviews
CellBxHealth enters master services agreement with AstraZeneca - marketscreener.com
AstraZeneca says Imfinzi approved in US for early bladder cancer - marketscreener.com
AstraZeneca (AZN) withdraws listing for 1.200% Notes due 2026 from NYSE - Stock Titan
AstraZeneca's Durvalumab Approved by FDA in Combination With BCG for Bladder Cancer - marketscreener.com
FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo - Pharmaceutical Technology
AstraZeneca PLC stock (US6549022043): FDA extends review for key breast cancer drug as London shares - AD HOC NEWS
ASTRAZENECA : Deutsche Bank keeps a Sell rating - marketscreener.com
PLATINUM INVESTMENT MANAGEMENT LTD's AstraZeneca PLC(AZN) Holding History - GuruFocus
AZN Stock Quote Price and Forecast - CNN
Why Are AstraZeneca, GSK and Hikma Lifting FTSE 100 Focus? - Kalkine Media
Expert View: Greencore, Autotrader, Watkin Jones, and Astrazeneca - Citywire
AstraZeneca PLC stock (US6549022043): FDA extends camizestrant review as investors weigh oncology mo - AD HOC NEWS
AstraZeneca plc stock (GB0009895292): FDA extends camizestrant review - AD HOC NEWS
FDA delays decision on AstraZeneca breast cancer pill - BioPharma Dive
AstraZeneca says FDA has delayed review of breast cancer therapy camizestrant - Seeking Alpha
FDA Delays AstraZeneca's Breast Cancer Drug Review: What to Know - PharmTech.com
AstraZeneca PLC stock (US6549022043): oncology pipeline, Obesity franchise and US market focus in th - AD HOC NEWS
FDA extends review period for AstraZeneca’s camizestrant breast cancer application - Investing.com India
AstraZeneca (AZN) sees FDA delay but EMA backs camizestrant combo - Stock Titan
Why Are AstraZeneca HSBC And Diageo Trending - Kalkine Media
AstraZeneca PLC ADR Dividends – BCBA:AZN.CI - TradingView
US FDA pushes back decision on Astrazeneca's camizestrant - Sharecast.com
US regulator delays decision on AstraZeneca cancer drug - Financial Times
AstraZeneca says FDA extends breast cancer drug review period - London South East
US FDA extends review of AstraZeneca’s experimental breast cancer pill - Reuters
FTSE 100: AstraZeneca (LSE:AZN) Faces Fresh Market Spotlight - Kalkine Media
US FDA decision date extended for SERENA-6 filing of camizestrant to enable review of additional data - AstraZeneca
AstraZeneca Unit Keeps Cancer Therapy IP Despite Stada Jab - Law360
Astrazeneca Pharma India March-quarter PAT 448.8 million rupees - marketscreener.com
AstraZeneca breast cancer drug camizestrant recommended for EU approval - Investing.com
Datroway extends survival in TNBC as AstraZeneca (NYSE: AZN) gains US ok - Stock Titan
AstraZeneca's Buy Rating Reiterated as BofA Notes 'Busy' Pipeline Path; Estimates Revised - marketscreener.com
CHMP backs AstraZeneca (AZN) and Daiichi Sankyo’s Enhertu for HER2‑positive solid tumours in EU - Stock Titan
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):